glp 1 inflammatory bowel disease Pharmacological interventions for obesity in patients with disease: A systematic review of GLP-1 receptor agonist efficacy and safety GLP-1RAs for IBD | Docwire

You should not take a GLP-1 drug if you have severe gastrointestinal conditions like inflammatory bowel disease (IBD) or gastroparesis or a personal or family history of multiple endocrine neoplasia 2A, multiple endocrine neoplasia 2B, medullary thyroid cancer, or pancreatitis

Nadeswaran also says kidney health needs to be closely monitored in seniors taking Ozyempic or other GLP-1 drugs

Lean body mass is affected by the degree of calorie restriction, rate of weight loss, optimal protein intake and the presence/absence of strength training

See also , Trends in FDA FY2022 Inspection-Based Warning Letters and Trends in FDA FY2023 Inspection-Based Warning Letters, supra notes 6 and 5

Xultophy, another Novo Nordisk product, combines insulin degludec (the active ingredient in Tresiba) with liraglutide (a GLP-1 receptor agonist) in a single injection